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A b s t r a c t  
The objective of the present research was to enhance the solubility of poorly water soluble 
antiretroviral drug i.e. efavirenz, by self nanoemulsifying drug delivery system (SNEDDS) and 
formulating it as tablets using 23 factorial designs. The SNEDDS were prepared using labrafac PG 
(15%) as oil, Tween 80 (19%) as surfactant and PEG 200 (38%) as co surfactant that yields the 
globule size of 142.7nm. The liquid SNEDDS were adsorbed onto aerosil which acts as carrier. The 
SEM of S-SNEDDS appeared as smooth-surfaced particles without any crystalline shape, indicating 
complete adsorption of SNEDDS. The absence of drug peak in S-SNEDDS thermogram was 
attributable to presence of drug in molecularly dissolved state in the vicinity of the lipid excipients. 
The 23 factorial designs were employed to optimize the concentration of Micro crystalline cellulose, 
PVP and sodium starch glycollate. The observed values were in close agreement with the predicted 
values thereby validating the feasibility of the optimization procedure in developing self 
nanoemulsifying tablets. The relative bioavailability of the S SNEDDS and pure drug were 388.49% 
and 95.39%, respectively. This confirms that the solubility of the drug has been increased leading to 
increase in the bioavailability of efavirenz. 
Keywords: Self nanoemulsifying drug delivery system, 23 factorial designs and bioavailability. 
Introduction 
Human Immunodeficiency Virus (HIV) a causative agent for 
Acquired Immuno deficiency Syndrome (AIDS) an immuno 
compromised condition that continues to be a frightening 
exterminator till date and more than 33 million people were affected 
worldwide [1]. Prevention of HIV infection to reduce the number of 
newly infected individuals is an international priority [2]. The main 
hindrances for highly compliant pharmacotherapy were less 
number of ARVs approved by the regulatory agencies and poor 
solubility profile [3]. Efavirenz belongs to the class of non-
nucleoside reverse transcriptase inhibitors that inhibits non-
competitively human HIV-1 reverse transcriptase [4]. Efavirenz 
belongs to BCS class 2 drug that has poor solubility and high 
permeability. The dissolution rate of the drug depends on aqueous 
solubility of a drug. The poor dissolution rate soaring from low 
solubility often results in the low bioavailability of orally 
administered drugs[5]. In order to achieve required therapeutic 
plasma concentrations after oral administration, poorly water 
soluble drugs usually requires high doses [6]. To improve the 
aqueous solubility various formulation strategies were reported in 
the literature including the use of surfactants, micronization, 
cyclodextrins, solid dispersions, permeation enhancers and lipids 
[7]. Self nanoemulsifying drug delivery systems (SNEDDS) are 
mixtures oil, surfactants, cosurfactants that form fine oil in water 
nanoemulsions when introduced into aqueous phases under gentle 
agitation [8]. After the successful development of Neoral 
Sandimmun the development of lipid formulations, especially 
SNEDDS, has received increased attention [9]. Due to high patient 
compliance, relatively easy to produce, easy to market, accurate 
dosing, good physical and chemical stability makes solid dosage 
forms like tablets and capsules were the most popular and 
preferred drug delivery forms. The prepared SNEDDS were 
formulated as tablets to get the advantage of improved solubility as 
well as to add the advantages of tablet [10]. Traditional 
experimentation approach on new pharmaceutical formulations 
development involves significant amount of time, materials and 
efforts to get valid results for a complex system. The major 
drawback of traditional experimentation also consequently 
associated with high cost, due to the existence of multiple factors 
that affects the formulation performance and manufacturing 
process. Recently, design of experiment (DOE) supported by 
statistical software has been reported as an efficient and powerful 
tool in the development and optimization of pharmaceutical dosage 
forms [11]. Factorial design is an efficient method of finding the 
relative significance of multiple variables and their interaction on 
the response or outcome of the study [12].  In the current research 
work, a three factor, two levels (23) full factorial design was used to 
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optimize the concentrations of diluent, binder and disintegrant on 
the responses hardness, disintegration time and dissolution.  
Materials and Methods 
Materials 
Efavirenz was provided as a gift sample from Shasun labs 
(Pondicherry, India). Labrafac PG was generous gift from 
Gattefosse, France (through Bombay College of Pharmacy, 
Mumbai). Porous Polystyrene beads were obtained as gift sample 
from Thermax Limited (Pune, India). Accurel was obtained from 
Membrana (Obernburg, Germany). Tween 80, PEG 200, MCC, 
sodium starch glycolate and polyvinylpyrollidone purchased from 
Loba chemie pvt ltd, Mumbai. All other chemicals and buffers used 
were of analytical grade.  
Preparation of Liquid SNEDDS 
Based on the preliminary studies (solubility studies, pseudoternary 
phase diagram and thermodynamic stability study) a self nano 
emulsifying system of efavirenz was prepared using labrafac PG as 
oil, Tween 80 as surfactant and PEG 200 as co surfactant [13].   
The preparation of the SNEDDS contains the following steps: 
1. 50mg of efavirenz was selected as the dose for incorporation 
into the oil phase. 
2. The surfactant and co surfactant was added to the oil phase and 
mixed with magnetic stirrer. 
3. Equilibrating in room temperature for 24hr before use.  
Preparation of Solid SNEDDS 
Aerosil, accurel MP 1000 and porous polystyrene spheres were 
used as the solid adsorbents to load efavirenz SNEDDS. The lipid 
formulation was added in increments and blended with the 
adsorbent at the following fixed efavirenz SNEDDS to adsorbent 
ratios by weight. Briefly, a constant aliquot of efavirenz SNEDDS 
was initially added to and mixed with the adsorbent in a mortar. 
The addition of lipid was suspended when non flowing mass is 
formed. The obtained mass was passed through 250 μm mesh to 
get uniformity in particle size. The flow behavior and loading 
efficiency of the adsorbed blend was then analyzed. The powder 
samples were stored in a desiccator until further evaluation. [14] 
Characterization of solid SNEDDS 
Scanning Electron Microscope 
The surface morphology of Solid SNEDDS was examined by 
scanning electron microscope (Hitachi S3400, Tokyo, Japan). The 
powder samples were glued and mounted on metal sample plates. 
After this the samples were gold coated with a sputter coater using 
an electrical potential of 2.0 kV at 25 mA for 10 min[15]. 
Differential Scanning Calorimetry 
The physical state of drug in solid SNEDDS was characterized by 
the differential scanning calorimetry thermogram analysis. The 
samples (about 3.00 mg) were placed in standard aluminum pans, 
and dry nitrogen was used as effluent gas. All samples were 
scanned at a temperature ramp speed of 5ĈC /min and the heat 
flow from 0 to 200ĈC [16]. 
Reconstitution properties of solid SNEDDS 
The mean globule size and polydispersity index (P.I.) of the 
resulting nanoemulsions were determined by photon correlation 
spectroscopy (which analyses the fluctuations in light scattering 
due to Brownian motion of the particles) using a Zetasizer 3000 
(Malvern Instruments Worcestershire, UK) Light scattering was 
monitored at 25ÀC at a 90Àangle. 
Experimental design 
The 23 full factorial designs were carried out systematically with 
three factors at two levels to prepare the efavirenz loaded 
SNEDDS tablets. A total of eight experimental trials were done at 
all possible combinations. Venturing taken during optimization of 
excipient the amount of MCC (A), PVP (B), and the amount of 
sodium starch glycolate (C) were selected as the independent 
variables that were varied at two levels (low and high). The levels 
of the variables studied were chosen so that their relative 
divergence was capable to have a quantifiable effect on the 
response, along with the information that the selected levels are 
within practical use [17, 18]. The responses (dependent variables) 
selected for the study were hardness, disintegration and 
cumulative drug release at 40 min. the statistical experimental 
design was generated and evaluated using Design-Expert 8.0.6.1 
software (Stat-Ease Inc., USA). The independent variables with its 
levels and the responses were shown in Table 1. 
 
Table 1: Variables in 23 factorial design 
 
Independent variable Levels 
Low High
A: MCC 200.00 300.00
B: PVP 12.00 20.00
C: SSG 8.00 16.00
Dependent variable
Y1 Hardness(kg) 
Y2 Disintegration Time(sec) 
Y3   % Cumulative drug release(%) 
Preparation of tablets 
The archetypal formula for preparation of efavirenz loaded 
SNEDDS tablet used in this study was given in Table 2. Tablets 
were punched by direct compression of mixtures on a B2 rotary 
tablet press (Remak, Ahmedabad) with flat plane face punches 
(punch diameter = 12mm) at 50 rpm. The excipients were 
screened through a #20 mesh. The final mixture to be compressed 
was prepared by mixing in a polyethylene bag manually for 10min. 
finally lubricant was added to this blend and motley properly for 2 
min. [19, 20] 
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Table 2: Typical Efavirenz loaded SNEDDS tablet composition 
 
Ingredient Qty (mg) 
Efavirenz loaded SNEDDS 100 
MCC 200/300 
PVP 12/20 
SSG 8/16 
Magnesium stearate 5 
Talc 5 
Lactose q.s 500 
Evaluation of tablets [21, 22] 
Hardness test 
Monsanto hardness tester (Tab-Machines Ltd., India) was used to 
determine tablet hardness. Ten tablets were chosen randomly from 
the composite samples for each of the tableting runs and the 
average value was determined. 
Disintegration test 
The tablet disintegration test was performed employing 
disintegration tester (Disintegration Tester ED-2AL, Electrolab, 
Mumbai) using demineralized water at 37μ2ĈC. The time required 
for tablet disintegration was determined by visual observation. 
Each value reported is the maximum time of 6 independent 
measurements 
Friability 
The friability of the tablets was determined by weighing 20 tablets 
dedusted prior testing in an analytical balance and moved for 4 min 
in an friability tester (Electrolab, EF2 Friabilator USP), set at speed 
of 25 revolutions per minute. After 4 min all loose dust was 
removed from the tablets, then they were reweighed and the 
percentage friability was calculated.  
Drug content estimation 
 The drug was extracted from S SNEDDS using methanol, suitably 
diluted and analyzed using UV-VIS spectrophotometer (Shimadzu 
UV 1800, Japan) at a λmax of 247nm. The experimental studies 
were performed in triplicate. 
Drug release 
In vitro drug dissolution tests were performed using the USP 24 
method with a dissolution apparatus 2 (Electrolab TDT-08L, 
Mumbai). The dissolution tests were carried out at 37μ0.5 ĈC in 900 
ml of 0.1 N HCl at 100 rpm. Results are averaged from three-
replicated experiments. During the release studies, 1 ml of SIF 
sample was withdrawn and quantification was performed using 
UV/Vis spectrophotometry. The withdrawn volume was replaced 
each time with fresh thermostated 0.1 N HCl [23] 
Pharmacokinetic studies 
The oral pharmacokinetics of drug was assessed in Wistar rats 
(220-250 g) of either sex at a dose equivalent to 10 mg/kg of drug. 
Two types of systems were systematically compared: (i) drug-
loaded S-SNEDDS, (ii) extemporaneous suspensions. In vivo study 
protocols were approved by the Institutional Animal Ethics 
Committee (Regd. No 107/2012). A wash out period of one month 
was given between testing of two products. 
After collecting the zero hour blood sample (blank), the product in 
the study was administered orally with 10 ml of water. No food or 
liquid other than water was permitted until 4 hours following the 
administration of the product. Blood samples (0.5 ml) were 
collected from tail vein at 0.25, 0.5, 1, 2, 4, 8 and 12 hours after 
administration. The blood samples were collected in heparinized 
tubes and were centrifuged at 10000 rpm for 10 min and the 
plasma separated was collected into dry tubes. All the samples 
were stored under refrigerated conditions prior to assay on the 
same day. Plasma concentrations of drug were determined by a 
known HPLC method after revalidation [15]. 
Stability studies  
The OPT S-SNEDDS formulation was subjected to stability studies, 
carried out at 40μ2◦C/70% μ 5% RH as per the ICH guidelines. The 
formulation was kept in air-tight glass vials and assayed 
periodically, at the time points of 0, 1, 3 and 6 months, for drug 
content and dissolution performance. 
Results and Discussion 
Preparation of liquid SNEDDS 
Efavirenz showed maximum solubility in Labrafac PG (Oil), tween 
80 (Surfactant) and PEG 200 (Co surfactant) hence these 
excipients were selected for the preparation of SNEDDS. The 
characteristic peaks of efavirenz (3319cm-1, 1060cm-1, 750 cm-1, 
1039 cm-1, 820 cm-1) were not affected and prominently observed 
in IR spectra of efavirenz along with other excipients(figure not 
given). This clearly shows there is no interaction between drug and 
excipients. 
Pseudo-ternary phase diagrams were constructed to identify the 
nanoemulsion regions and to optimize the concentration of the 
selected vehicles. The optimized formulation labrafac PG(15%) as 
oil, Tween 80(19%) as surfactant and PEG 200(38%) as co 
surfactant were robust to all dilutions and did not show any phase 
separation or precipitation. The globule size of the formulation was 
found to be 142.7nm.  
Preparation of S-SNEDDS 
The S-SNEDDS were prepared using carriers like aerosil, accurel 
and porous polystyrene beads. The mean particle size of aerosil 
was 12nm and has specific surface area (BET) 380μ30 m2/g. 
Because of its small particle size and large specific surface area 
the S-SNEDDS prepared with aerosil had high loading efficiency 
and desirable flow characteristics (table 3). So it was selected as a 
suitable excipient for the preparation of S-SNEEDS.  
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Table 5: Observed Response in 23 Factorial Design for Efavirenz loaded SNEDDS tablet 
 
 
Std 
 
 
Run 
Factor 1 Factor 2 Factor 3 Response 1 Response 2 Response 3
A:MCC 
mg 
B:PVP 
mg 
C:SSG
mg 
Hardness
kg 
Disintegration 
Time (Sec) 
% Cumulative 
drug release 
2 1 300.00 12.00 8.00 5.9 125 76.4
8 2 300.00 20.00 16.00 4.6 98 87.3
1 3 200.00 12.00 8.00 5.2 112 82.6
5 4 200.00 12.00 16.00 3.4 72 99.2
7 5 200.00 20.00 16.00 4.3 92 90.6
4 6 300.00 20.00 8.00 7.1 152 68.5
3 7 200.00 20.00 8.00 6.3 138 71.2
6 8 300.00 12.00 16.00 4 85 95.4
 
 
The results of ANOVA indicated that all models were significant (p 
< 0.05) for all response parameters investigated. Model 
simplification was carried out by eliminating non-significant terms 
(p > 0.05) in polynomial equations. Values of "Prob > F" less than 
0.0500 in all the cases indicates model terms are significant. The 
Pred R-Squared is in reasonable agreement with the Adj R-
Squared. The signal to noise ratio is measured by Adeq Precision 
and ratio greater than 4 is desirable. The value shows much higher 
than 4 confirms an adequate signal (Table 6). 
 
Table 6: Summary of results of regression analysis for responses 
 Value F-value p-value
                  Hardness 
R-Square 0.9865  
97.16 0.0003 Adj R-Squared 0.9763 
Pred R-Squared 0.9458 
Adeq Precision 26.291 
             Disintegration Time 
R-Square 0.9867  
99.08 0.0003 Adj R-Squared 0.9768 
Pred R-Squared 0.9469 
Adeq Precision 26.275 
     % Cumulative Drug Release 
R-Square 0.9950  
266.61 < 0.0001 Adj R-Squared 0.9913 
Pred R-Squared 0.9801 
Adeq Precision 42.528 
 
 
Figure 3 shows the effect plots for hardness, disintegration time 
and friability, where negative values indicate a negative effect of a 
specific variable on the response factors. The application of 
factorial design yielded the following regression equations. 
Hardness =+4.775+6.0E-003 * MCC+0.118 * PVP-0.256* SSG 
Disintegration Time=+105.0+0.115* MCC+2.68 * PVP-5.62 * SSG 
 % Cumulative drug release =+84.22-0.04 * MCC-1.12 * PVP+2.30 
* SSG 
 
Hardness, Disintegration time and % Cumulative drug release 
values for all the eight formulations varied from 3.4 to 7.1 kg, 72-
152s and 68.5-99.2% respectively. These outcomes depicts that 
the variables chosen have strong influence on the selected 
responses. 
 
 
 
 
 
Figure. 3. Three-dimensional response surface plot depicting the impact of MCC:PVP, MCC:SSG and SSG:PVP on hardness, disintegration time  
and  % drug release respectively 
 
The MCC PH 101 having the particle size of 50øm that absorbs the 
any squeezing of lipid occurs while punching of tablets. MCC has 
good wicking and absorbing capacities. PVP K 30 is used because 
of its directly compressible property that acts as binder. SSG acts 
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as super disintegrant. [MCC accelerates water penetration into 
tablets can cause easily swelling of SSG, and this reveals readily 
superdisintegrant property of SSG [22]. The excellent batch 
flowability and compressibility properties were attributed to the 
presence of microcrystalline cellulose, MCC, (Avicel 102), which is 
an excellent filler/flow-aid for direct compression. [24] 
The figure 3. exhibits, as the concentration of PVP increases, the 
hardness of the tablets increases due to the increased bonding 
between the particles. Tablets of MCC disintegrated rapidly due to 
the rapid passage of water into the tablets resulting in the 
instantaneous rupture of the hydrogen bonds. Disintegration occurs 
by rapid uptake of water followed by rapid and enormous swelling 
by SSG. It was essential to use suitable inert compression diluents 
to improve the compactibility of tablets. In all the formulations, the 
hardness test indicated good mechanical strength and friability was 
less than 1%, which indicated that the tablets had a good 
mechanical resistance. The extent of dissolution, however, is 
dependent on the reversible attraction and surface adsorption of 
efavirenz and the oily formulation onto the adsorbents. Therefore, 
physical properties of the ingredients used to prepare the solid 
compacts have a profound effect on the emulsion release rate. 
This relationship between the formulation ingredients (independent 
variables) and emulsion release rates (dependent variables) was 
elucidated using 3 D graphs. [25]. Drug content was found to be 
98-102% which was within the limits. 
To optimize the final tablet formulation, the required limits of the 
response values were clearly defined, and the combinations of 
variables which resulted in tablets meeting the required 
specifications were calculated using the software to obtain tablets 
with the following properties: a hardness of 4, disintegration time of 
less than 80 sec and % cumulative release of more than 95%.  
To verify the reproducibility, a new formulation as shown in Table 7 
was prepared according to the predicted levels and evaluated. The 
overlapping of the obtained result over the predicted values 
confirms the practicability and validation of the model
 
Table 7: Optimisation of final tablet 
Number MCC 
(mg) 
PVP
(mg) 
SSG
(mg) 
Hardness
(kg) 
Disintegration 
Time(sec) 
% Cumulative 
drug release 
Predicted 278.75 12.00 15.88 4 79.9 96.1 
Actual 278.75 12.00 15.88 4 78 97 
Relative 
error(%)    0 2.37 0.9 
. 
Pharmacokinetic studies  
Plasma samples were analyzed for efavirenz employing reverse 
phase HPLC (RP-HPLC). The mobile phase consisted of 
acetonitrile:water (70:30). Each of the plasma samples was thawed 
to room temperature. One milliliter of diethyl-ether was added to it 
and mixed using a vortex mixer for 30 s. The upper organic phase 
was transferred and evaporated to dryness on a water bath at 
50◦C. To each dry residue, 0.5 ml of mobile phase was added, and 
mixed using the vo\ rtex mixer for 10 s to reconstitute the same. 
The reconstituted sample was transferred to the HPLC vials and 
injected into the integrated liquid chromatographic system 
Shimadzu LC-2010 HT equipped with a UV detector and a C18 
column. The flow rate was kept at 1 ml min-1 and the UV detector 
was set at an absorption max of 247 nm. From the chromatogram 
efavirenz was observed at retention time of 5.6 min [3, 26]. 
Table 8: Pharmacokinetic parameters 
Product Cmax (mcg/ml) Tmax (h) Kel T1/2 (AUC)0t 
Efavirenz 10.46 3.7 0.1776 3.9 95.39 
Efavirenz S SNEDDS 42.6 1 0.2038 3.4 388.49 
 
Table 8 shows significant improvement of drug absorption for the S 
SNEDDS than the pure drug. The results showed that Cmax of S 
SNEDDS was higher than that of pure drug. Additionally, Tmax of 
the S SNEDDS was all shorter than that of the pure drug, 
suggesting that SE technique could improve drug release and 
absorption in GIT. The relative bioavailability of the S SNEDDS and 
pure drug were 388.49% and 95.39%, respectively. It indicated that 
the absorption of efavirenz was evidently improved after it was 
dispersed in solid SE formulations as a dissolved state. 
Stability studies  
The optimized formulation was stable throughout the study period. 
There is no significant change in drug content and dissolution 
performance. 
Conclusion 
These current research evidenced the successful loading of 
efavirenz SNEDDS in aerosil by adsorption technique. Self 
emulsifying properties were still retained after loading and no 
significant changes in the particle size were observed. The S 
SNEDDS tablets were prepared by 23 factorial design using design 
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expert software. The results of ANOVA indicated that all models 
were significant. The model was used to predict the levels of the 
factors A, B and C required obtaining an optimum formulation with 
moderate hardness, minimum disintegration time and maximum % 
drug release. The observed values were in close agreement with 
the predicted values thereby validating the feasibility of the 
optimization procedure in developing self nanoemulsifying tablets. 
The in vivo study in wistar rats showed significantly enhanced 
bioavailability from S-SNEDDS compared with pure drug. 
Considering the significant increment of pharmacokinetic 
parameters (AUC and Cmax) and the thermodynamically and 
chemically stable drug delivery system, S SNEDDS may be an 
effective formulation strategy for the other BCS class II and IV 
drugs. 
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